Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind,
placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC-
93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study
will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase.
Participants will be randomized at the beginning of the study into 3 treatment arms:
Placebo for Induction and Maintenance
CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once
every other week for Maintenance
CC-93538 360 mg SC once weekly for Induction and Maintenance
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.